Marijuana Addiction: Understanding Cannabis Use Disorder and Recovery

Clinically reviewed by Dr. Ponlawat Pitsuwan, Physician and Addiction Medicine Specialist, Phuket Island Rehab

The Neuroscience of Cannabis Dependence

To understand why marijuana can become addictive, it is necessary to understand the endocannabinoid system (ECS). This system consists of two primary receptors, CB1 and CB2, their endogenous ligands (anandamide and 2-AG), and the enzymes that synthesise and degrade these compounds (FAAH and MAGL). The ECS regulates mood, appetite, pain perception, sleep, memory, and stress response. It functions as a retrograde signalling system, meaning endocannabinoids are released by postsynaptic neurons and travel backward to modulate neurotransmitter release from presynaptic terminals.

Delta-9-tetrahydrocannabinol (THC), the primary psychoactive compound in cannabis, is a partial agonist at CB1 receptors. When THC floods the system through regular use, the brain responds by downregulating CB1 receptor density and sensitivity. This neuroadaptation means that the endocannabinoid system can no longer function normally without THC. Natural mood regulation, appetite signalling, and stress buffering become impaired, driving the user to continue consuming cannabis simply to feel baseline normal. This is the neurobiological basis of dependence.

DSM-5 Criteria for Cannabis Use Disorder

The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) recognises cannabis use disorder as a diagnosable condition. It is defined by a problematic pattern of cannabis use leading to clinically significant impairment or distress, with at least two of eleven criteria present within a 12-month period. These criteria include using more cannabis than intended, persistent desire or unsuccessful efforts to cut down, spending a great deal of time obtaining or using cannabis, craving, failure to fulfil major role obligations, continued use despite social problems, giving up important activities, use in physically hazardous situations, continued use despite knowledge of physical or psychological problems, tolerance, and withdrawal.

Severity is classified as mild (2 to 3 criteria), moderate (4 to 5 criteria), or severe (6 or more criteria). Research from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC-III) found that approximately 2.5 percent of American adults met criteria for CUD in the past year, with the highest rates among 18 to 29-year-olds.

Risk Factors for Developing Cannabis Addiction

Not everyone who uses cannabis develops a use disorder, and understanding the risk factors helps explain individual vulnerability. Age of first use is one of the strongest predictors: individuals who begin using before age 18 are four to seven times more likely to develop CUD than those who start as adults. This is because the adolescent brain is still undergoing critical development, particularly in the prefrontal cortex and the endocannabinoid system itself.

Genetic factors account for an estimated 50 to 70 percent of the variability in CUD risk. Specific polymorphisms in the CNR1 gene (which encodes the CB1 receptor) and the FAAH gene (which encodes the enzyme that breaks down anandamide) have been associated with increased susceptibility. Family history of any substance use disorder elevates risk, as do co-occurring mental health conditions, particularly anxiety disorders, depression, ADHD, and PTSD, where cannabis may initially be used as self-medication.

Frequency and potency of use are modifiable risk factors. Daily or near-daily use dramatically increases dependence risk compared to weekly or occasional use. The shift toward high-potency products, including concentrates (dabs) that can contain 60 to 90 percent THC, has compressed the timeline from first use to dependence development.

The Impact of Long-Term Cannabis Use

Chronic heavy cannabis use affects multiple body systems beyond the brain’s reward circuitry. Cognitive effects include impaired working memory, reduced processing speed, and diminished executive function. While some cognitive recovery occurs with sustained abstinence, neuroimaging studies suggest that individuals who began heavy use during adolescence may show persistent structural and functional changes in the hippocampus and prefrontal cortex.

Respiratory effects from smoked cannabis parallel many of those seen with tobacco: chronic bronchitis, increased mucus production, airway inflammation, and impaired mucociliary clearance. Cardiovascular research has identified an elevated risk of tachycardia, orthostatic hypotension, and, in susceptible individuals, acute coronary events during the period immediately following use. Mental health consequences of chronic use include increased risk of psychotic disorders (particularly in those with genetic predisposition), amotivational syndrome characterised by apathy and reduced goal-directed behaviour, and worsening of pre-existing anxiety and depressive conditions despite the perception that cannabis helps manage these symptoms.

Cannabis Withdrawal Syndrome

Cannabis withdrawal syndrome is recognised in both DSM-5 and ICD-11, settling a longstanding debate about whether cannabis produces “real” withdrawal. The syndrome typically begins within 24 to 72 hours of cessation in daily users, peaks at approximately days 4 to 7, and resolves within 1 to 2 weeks for most individuals, though sleep disturbance may persist for 30 days or longer.

Core withdrawal symptoms include irritability and anger, anxiety and nervousness, sleep difficulty (insomnia, vivid dreams), decreased appetite and weight loss, restlessness, depressed mood, and at least one physical symptom such as abdominal pain, shakiness, sweating, fever, chills, or headache. The vivid dreaming experienced during cannabis withdrawal is particularly noteworthy: THC suppresses REM sleep, and its removal triggers a REM rebound that produces intensely vivid and often disturbing dreams.

When Substance Use Has Become More Than Occasional

Many people who develop cannabis dependence describe a gradual shift from recreational use to daily use to reliance. The transition often happens without a clear turning point. If you find that cannabis has moved from something you choose to do occasionally to something you need to do every day, that you feel anxious or irritable without it, that you have tried to cut down or stop and found yourself unable to, or that your use has begun to affect your relationships, work performance, or motivation, these are clinical indicators that professional assessment is warranted.

Cannabis use disorder is not about willpower. It is a condition rooted in measurable changes to the brain’s endocannabinoid system and reward circuitry. Recognising it as such is the first step toward effective treatment.

Treatment for Cannabis Addiction at Phuket Island Rehab

At Phuket Island Rehab, cannabis use disorder treatment begins with a comprehensive assessment of use patterns, co-occurring conditions, and the individual’s goals for recovery. Unlike substances that require medical detox, cannabis withdrawal is managed primarily through supportive care: sleep hygiene protocols, nutritional support to address appetite disruption, exercise programming to boost natural endocannabinoid tone, and short-term symptomatic relief for insomnia or anxiety where clinically appropriate.

The core of treatment is psychotherapy. Cognitive behavioural therapy (CBT) is the most evidence-supported intervention for CUD, targeting the automatic thoughts and behavioural patterns that maintain daily use. Motivational enhancement therapy (MET) addresses ambivalence about quitting, which is particularly relevant for cannabis, where societal normalisation of use can undermine motivation for change. Contingency management provides structured reinforcement for sustained abstinence.

For clients with co-occurring conditions, integrated treatment addresses both simultaneously. If cannabis was being used to manage anxiety, the treatment plan includes evidence-based anxiety management. If it was masking depression or PTSD, those conditions receive direct clinical attention. Treating the underlying driver of use is essential for preventing relapse.

The residential setting removes the environmental cues and social dynamics that maintain cannabis use. Many of our clients describe this separation from their daily using context as the single most important factor in achieving the initial weeks of abstinence needed for the brain to begin recovering its natural endocannabinoid function.

Frequently Asked Questions

Is marijuana really addictive?

Yes. Cannabis use disorder is recognised in both DSM-5 and ICD-11. Approximately 10 percent of all cannabis users and up to 30 percent of those who start before age 18 develop dependence. The condition involves measurable downregulation of CB1 receptors in the endocannabinoid system, produces a defined withdrawal syndrome, and meets the same diagnostic framework applied to other substance use disorders.

How do I know if I have cannabis use disorder?

Key indicators include using more cannabis or for longer than intended, unsuccessful efforts to cut down, spending significant time obtaining or using cannabis, craving, reduced participation in previously enjoyed activities, and continuing use despite negative consequences. If two or more DSM-5 criteria are present within a 12-month period, a clinical diagnosis of CUD may be appropriate. A professional assessment can provide clarity.

Does cannabis withdrawal require medical detox?

Cannabis withdrawal is not medically dangerous in the same way as alcohol or benzodiazepine withdrawal, so formal medical detox is not usually required. However, the withdrawal symptoms, particularly insomnia, irritability, anxiety, and cravings, are significant enough to cause most unsupported quit attempts to fail. Structured support during the withdrawal period greatly improves the likelihood of sustained abstinence.

How long does it take to recover from daily cannabis use?

Physical withdrawal symptoms resolve within 1 to 2 weeks for most people, though sleep disruption may persist for up to 30 days. Neuroimaging research shows that CB1 receptor density begins recovering within 2 days of abstinence and approaches normal levels by approximately 28 days. Full cognitive recovery, particularly for long-term heavy users, may take several months. Psychological recovery, including developing new coping strategies and addressing the reasons for use, is an ongoing process supported by therapy.

Is high-potency cannabis more addictive than regular marijuana?

Evidence strongly suggests yes. Higher THC concentrations produce greater CB1 receptor occupancy per use episode, accelerating the neuroadaptation process that leads to dependence. A 2019 study published in The Lancet Psychiatry found that daily use of high-potency cannabis (10%+ THC) was associated with five times greater odds of developing a psychotic disorder compared to never-users, and dependence rates in high-potency users also appear to be elevated. Concentrates containing 60 to 90 percent THC represent an extreme end of this potency spectrum.

Can I use CBD to help with cannabis addiction?

Preliminary research suggests that cannabidiol (CBD) may reduce cue-induced craving and anxiety in people with CUD, and early clinical trials are exploring its potential as an adjunct treatment. However, evidence is not yet sufficient to recommend CBD as a standalone treatment for cannabis addiction. For individuals in early recovery, using any cannabis-derived product can also serve as a behavioural trigger that undermines abstinence goals. Discuss any interest in CBD-based approaches with your treating clinician.

Sources: Hasin DS et al. Prevalence of Marijuana Use Disorders in the United States Between 2001-2002 and 2012-2013. JAMA Psychiatry. 2015;72(12):1235-1242. Di Forti M et al. The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI). Lancet Psychiatry. 2019;6(5):427-436. American Psychiatric Association. DSM-5 Cannabis Use Disorder diagnostic criteria. National Institute on Drug Abuse (NIDA). Cannabis (Marijuana) Research Report, 2020.

Clinical entities: cannabis use disorder (CUD), delta-9-tetrahydrocannabinol (THC), endocannabinoid system (ECS), CB1 receptor, CB2 receptor, anandamide, 2-arachidonoylglycerol (2-AG), FAAH enzyme, MAGL enzyme, CNR1 gene polymorphism, CB1 receptor downregulation, cannabis withdrawal syndrome, REM rebound, DSM-5 CUD criteria, ICD-11, NESARC-III, Cognitive Behavioural Therapy (CBT), Motivational Enhancement Therapy (MET), contingency management, cannabidiol (CBD), The Lancet Psychiatry, Dr. Ponlawat Pitsuwan, Physician, Phuket Island Rehab